Literature DB >> 11744799

Retrospective study of children with acute pyelonephritis. Evaluation of bacterial etiology, antimicrobial susceptibility, drug management and imaging studies.

L Ghiro1, A T Cracco, M Sartor, S Comacchio, G Zacchello, R Dall'Amico.   

Abstract

The purpose of the study was to investigate the management of pyelonephritis in a large Italian pediatric population. A total of 1,333 patients (36% male) were considered. Escherichia coli was the most frequently isolated agent (89.9%), followed by Proteus mirabilis (3.6%) and Klebsiella oxytoca (2.1%). 27% of microorganisms were resistant to amoxicillin, 4% to amoxicillin/clavulanic acid, 11% to trimethoprim-sulfamethoxazole, 2.4% to gentamicin and less than 2% to ceftazidime. Despite this resistance pattern showing that oral antibiotics, such as amoxicillin/clavulanic acid, are effective in vitro as well as parenteral antimicrobials, a parenteral antibiotic was given initially to 756 (57.2%) children. A prophylactic regimen was started in 922 patients with a rate of reinfection during prophylaxis of 9.5%; a higher rate of reinfection was observed in patients with reflux (25%) compared to children without reflux (3%) (p < 0.0001). Vesicoureteral reflux was demonstrated in 30% of patients. The number of renal abnormalities detected by DMSA in patients with and without reflux was significantly different (p < 0.001). CRP was higher in patients with scars (p < 0.02). In conclusion, pyelonephritis represents a common disease with about 2,500 days of hospitalization per year in the Veneto Region where there is a pediatric population of about 800,000 under 15 years of age. The results of antimicrobial in vitro tests indicate that amoxillicin/clavulanic acid could represent the antibiotic of choice. The high frequency of malformations, observed even in children between 6 and 12 years of age, may suggest the need of an imaging study including DMSA scan and VCUG in all age groups. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11744799     DOI: 10.1159/000046308

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  7 in total

Review 1.  Urinary tract infections in children: recommendations for antibiotic prophylaxis and evaluation. An evidence-based approach.

Authors:  Paul A Merguerian; Einar F Sverrisson; Daniel B Herz; Leslie T McQuiston
Journal:  Curr Urol Rep       Date:  2010-03       Impact factor: 3.092

2.  Klebsiella oxytoca Complex: Update on Taxonomy, Antimicrobial Resistance, and Virulence.

Authors:  Jing Yang; Haiyan Long; Ya Hu; Yu Feng; Alan McNally; Zhiyong Zong
Journal:  Clin Microbiol Rev       Date:  2021-12-01       Impact factor: 50.129

3.  Urinary tract infections: to prophylaxis or not to prophylaxis?

Authors:  Giovanni Montini; Ian Hewitt
Journal:  Pediatr Nephrol       Date:  2009-05-15       Impact factor: 3.714

4.  Long-term resistance trends of uropathogens and association with antimicrobial prophylaxis.

Authors:  Maria Bitsori; Sofia Maraki; Emmanouil Galanakis
Journal:  Pediatr Nephrol       Date:  2013-12-21       Impact factor: 3.714

5.  Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial.

Authors:  Giovanni Montini; Antonella Toffolo; Pietro Zucchetta; Roberto Dall'Amico; Daniela Gobber; Alessandro Calderan; Francesca Maschio; Luigi Pavanello; Pier Paolo Molinari; Dante Scorrano; Sergio Zanchetta; Walburga Cassar; Paolo Brisotto; Andrea Corsini; Stefano Sartori; Liviana Da Dalt; Luisa Murer; Graziella Zacchello
Journal:  BMJ       Date:  2007-07-04

Review 6.  Dimercaptosuccinic acid scan or ultrasound in screening for vesicoureteral reflux among children with urinary tract infections.

Authors:  Nader Shaikh; Russell B Spingarn; Stephanie W Hum
Journal:  Cochrane Database Syst Rev       Date:  2016-07-05

7.  Role of Uropathogenic Escherichia coli Virulence Factors in Development of Urinary Tract Infection and Kidney Damage.

Authors:  Justyna Bien; Olga Sokolova; Przemyslaw Bozko
Journal:  Int J Nephrol       Date:  2012-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.